Physician profile
James Albert Tarbox
NPI 1700063591
$12,234.22
in general payments reported to CMS, 2019-2025
26 companies · $8,161 in 2025
The $8,161 reported for 2025 was more than what 88% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,057 · 2020: $169 · 2021: $520 · 2022: $403 · 2023: $815 · 2024: $1,110 · 2025: $8,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,752 · Food and Beverage: $3,505 · Travel and Lodging: $740 · Education: $88.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,752.00 |
| Food and Beverage | $3,505.07 |
| Travel and Lodging | $740.09 |
| Education | $88.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $6,735.64 | 2025 | Andembry |
| Astrazeneca Pharmaceuticals Lp | $1,087.35 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $918.65 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $770.30 | 2021-2025 | Tezspire, Actimmune |
| Regeneron Healthcare Solutions, INC. | $440.48 | 2019-2025 | Dupixent |
| Genzyme Corporation | $347.08 | 2019-2025 | |
| Genentech USA, INC. | $272.17 | 2023-2025 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.70 | 2019-2024 | Spevigo |
| Lilly USA, LLC | $203.70 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $181.06 | 2019-2024 | |
| Abbvie INC. | $123.42 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $117.29 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $115.43 | 2020-2025 | Takhzyro |
| Horizon Therapeutics Plc | $98.14 | 2019-2023 | Actimmune |
| Blueprint Medicines Corporation | $97.97 | 2024 | Ayvakit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $96.74 | 2023 | Da Vinci Surgical System |
| Sanofi-Aventis U.S. LLC | $88.99 | 2025 | |
| Ionis Pharmaceuticals, INC. | $68.80 | 2025 | Dawnzera |
| Biocryst US Sales Co., LLC | $62.30 | 2025 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $34.80 | 2020 | |
| Allergan, INC. | $32.93 | 2019 | |
| Mallinckrodt Hospital Products INC. | $29.01 | 2025 | Acthar |
| Insmed, INC. | $26.58 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $21.31 | 2024 | |
| Merck Sharp & Dohme LLC | $14.29 | 2019 | |
| Mylan Specialty L.P. | $14.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Tarbox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.